Cancer Nanotheranostics
- Authors: Ezgi Nurdan Yenilmez Tunoglu, Berçem Yeman, Merve Biçen, Servet Tunoglu, Yousef Rasmi, Yusuf Tutar6
-
View Affiliations Hide Affiliations6 University of Health Sciences, Hamidiye Health Sciences Institute, Division of Molecular Medicine, 34668, Istanbul, Turkey
- Source: Advances in Cancer Nanotheranostics for Experimental and Personalized Medicine , pp 1-17
- Publication Date: June 2020
- Language: English
Cancer Nanotheranostics, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789811456916/chapter-1-1.gif
Molecular profiling of diseases identifies specific cancer-causing genes and associated networks. Administered drug displays different therapeutic efficiency depending on individual cancer subtype and therapeutic responses. Personalized medicine helps designing treatment methods for individual patients with distinct diseases. For complete understanding of patients pathophysiology, different omics data types are integrated. These data can be derived from whole-exome sequencing, metabolomics, pharmacogenomics, and proteomics. Pharmacogenomics deals with the interaction of drug and patients genetic make-up and metabolomics reveals custom regulation of biochemical pathways in patients. Transcriptomics and proteomics analyze organism tissue or cell type in cancer and play even more relevant role in personalized medicine. Since associated genetic anomalities and metabolic profiles influence therapy response, a continuous evolution of cancer nanotheranostics helps preventing and treating the disease more precisely.
-
From This Site
/content/books/9789811456916.chapter-1dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
